Table 4.

Adverse Events over Time During Treatment with GPB

	Switch Over Period		12 Months Treatment with GPB
	NaPBA 1–7 days (N=26)	GPB 7–10 days (N=26)	0–<3 Months (N=49)	3–<6 Months (N=48)	6–<9 Months (N=47)	9–<12 Months (N=46)	Overall 12 Months (N=49)
Upper respiratory tract infection	0	1 (3.8%)	8 (16.3%)	7 (14.6%)	5 (10.6%)	9 (19.6%)	19 (38.8%)
Vomiting	0	3 (11.5%)	8 (16.3%)	3 (6.3%)	6 (12.8%)	7 (15.2%)	18 (36.7%)
Hyperammonaemia	0	0	3 (6.1%)	5 (10.4%)	4 (8.5%)	4 (8.7%)	12 (24.5%)
Pyrexia	0	0	5 (10.2%)	3 (6.3%)	3 (6.4%)	3 (6.5%)	11 (22.4%)
Cough	0	0	6 (12.2%)	2 (4.2%)	1 (2.1%)	1 (2.2%)	9 (18.4%)
Diarrhoea	0	0	4 (8.2%)	2 (4.2%)	2 (4.3%)	3 (6.5%)	9 (18.4%)
Gastroenteritis	0	0	2 (4.1%)	2 (4.2%)	1 (2.1%)	2 (4.3%)	6 (12.2%)
Nasopharyngitis	0	0	1 (2.0%)	1 (2.1%)	2 (4.3%)	2 (4.3%)	6 (12.2%)
Decreased appetite	1 (3.8%)	0	4 (8.2%)	1 (2.1%)	2 (4.3%)	1 (2.2%)	6 (12.2%)
Pharyngitis streptococcal	0	0	2 (4.1%)	2 (4.2%)	1 (2.1%)	0	5 (10.2%)